Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. A medication used to treat fungal infection in patients with weak immune function.
- Mechanism
- Curator reviewed
As a triazole antifungal agent, posaconazole exerts its antifungal activity through blockage of the cytochrome P-450 dependent enzyme, sterol 14α-demethylase, in fungi by binding to the heme cofactor located on the enzyme. This leads to the inhibition of the synthesis of ergosterol, a key component of the fungal cell membrane, and accumulation of methylated sterol precursors. This results in inhibition of fungal cell growth and ultimately, cell death.
- Primary indication
- For prophylaxis of invasive Aspergillus and Candida infections in patients, 13 years of age and older, who are at high risk of developing these infections due to being severely immunocompromised as a result of procedures...Curator reviewed · 15 structured indications
- Formula / weight
- C37H42F2N8O4 · 700.7774 g/mol (avg)
- First approval
- Canada, 2011 · United States, 2006 · European Union, 2016
- Code names
- SCH-56592 · Schering 56592
- Brand names
Resolves to
RAGOYPUPXAKGKH-XAKZXMRKSA-NSMILESCC[C@@H]([C@H](C)O)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=NC=N3)(C2)C2=C(F)C=C(F)C=C2)C=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Posaconazole, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account